References
- Cao Y (2009). Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci Signal, 2, e1. https://doi.org/10.1126/scisignal.262tr1
- Chen YJ, Kuo CD, Tsai YM, et al (2008). Norcantharidin induces anoikis through Jun-N-terminal kinase activation in CT26 colorectal cancer cells. Anticancer Drugs, 19, 55-64. https://doi.org/10.1097/CAD.0b013e3282f18826
- Chen YJ, Shieh CJ, Tsai TH, et al (2005). Inhibitory effect of norcantharidin, a derivative compound from blister beetles, on tumor invasion and metastasis in CT26 colorectal adenocarcinoma cells. Anticancer Drugs, 16, 293-9. https://doi.org/10.1097/00001813-200503000-00008
- Carmeliet P(2005). Angiogenesis in life, disease and medicine. Nature, 438, 932-6. https://doi.org/10.1038/nature04478
- Des Guetz G, Uzzan B, Nicolas P, et al (2006). Microvessel density and VEGF expression are prognostic factors in colorectal cancer. Meta-analysis of the literature. Br J Cancer, 94, 1823-32. https://doi.org/10.1038/sj.bjc.6603176
- De Vita F, Orditura M, Lieto E, et al (2004). Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. Cancer, 100, 270-8. https://doi.org/10.1002/cncr.11911
- Ferrara N(2005). VEGF as a therapeutic target in cancer. Oncology, 69, 11-6. https://doi.org/10.1159/000088479
- Folkman J (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med, 1, 27-31. https://doi.org/10.1038/nm0195-27
- Fang Y, Tian SL, Li KQ, et al (1993). Studies on antitumor agents II: synthesis and anticancer activity of dehydrogenated carboncyclic analogs of norcantharidin. Yao Xue Xue Bao, 28, 931-5 (in Chinese).
- Greenberg JI, Shields DJ, Barillas SG, et al (2008). A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature, 456, 809-13. https://doi.org/10.1038/nature07424
- Graziano F, Cascinu S (2003). Prognostic molecular markers for planning adjuvant chemotherapy trials in Dukes' B colorectal cancer patients: how much evidence is enough? Ann Oncol, 14, 1026-38. https://doi.org/10.1093/annonc/mdg284
- Gille H, Kowalski J, Li B, et al (2001). Analysis of biological effects and signaling properties of Flt-1 (VEGFR-1) and KDR (VEGFR-2). A reassessment using novel receptorspecific vascular endothelial growth factor mutants. J Biol Chem, 276, 3222-30. https://doi.org/10.1074/jbc.M002016200
- Heath VL, Bicknell R (2009). Anticancer strategies involving the vasculature. Nat Rev Clin Oncol, 6, 395-404. https://doi.org/10.1038/nrclinonc.2009.52
- Hanahan D, Weinberg RA (2000). The hallmarks of cancer. Cell, 100, 57-70. https://doi.org/10.1016/S0092-8674(00)81683-9
- Jain RK, Duda DG, Clark JW, et al (2006). Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol, 3, 24-40.
- Kitadai Y (2010). Angiogenesis and lymphangiogenesis of gastric cancer. J Oncol, 2010, 468725.
- Karamysheva AF (2008). Mechanisms of angiogenesis. Biochemistry (Mosc), 73, 751-62. https://doi.org/10.1134/S0006297908070031
- Kerbel RS (2008). Tumor angiogenesis. N Engl J Med, 358, 2039-49. https://doi.org/10.1056/NEJMra0706596
- Mohr B, Illmer T (2005). Structural chromosomal aberrations in the colon cancer cell line HCT 116--results of investigations based on spectral karyotyping. Cytogenet Genome Res, 108, 359-61. https://doi.org/10.1159/000081532
- Peng C, Liu X, Liu E, et al (2009). Norcantharidin induces HT-29 colon cancer cell apoptosis through the alphavbeta6- extracellular signal-related kinase signaling pathway. Cancer Sci, 100, 2302-8. https://doi.org/10.1111/j.1349-7006.2009.01320.x
- Pang RW, Poon RT (2006). Clinical implications of angiogenesis in cancers. Vasc Health Risk Manag, 2, 97-108. https://doi.org/10.2147/vhrm.2006.2.2.97
- Quesada AR, Munoz-Chapuli R, Medina MA (2006). Antiangiogenic drugs: from bench to clinical trials. Med Res Rev, 26, 483-530. https://doi.org/10.1002/med.20059
- Rodrigo JP, Cabanillas R, Chiara MD, et al (2009). Prognostic significance of angiogenesis in surgically treated supraglottic squamous cell carcinomas of the larynx. Acta Otorrinolaringol Esp, 60, 272-7 (in Spanish). https://doi.org/10.1016/j.otorri.2008.12.001
- Svagzdys S, Lesauskaite V, Pavalkis D, et al (2009). Microvessel density as new prognostic marker after radiotherapy in rectal cancer. Bmc Cancer, 9, 95. https://doi.org/10.1186/1471-2407-9-95
- Shibuya M, Claesson-Welsh L (2006). Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Experimental Cell Res, 312, 549-60. https://doi.org/10.1016/j.yexcr.2005.11.012
- Tanigawa N, Amaya H, Matsumura M, et al (1997). Tumor angiogenesis and mode of metastasis in patients with colorectal cancer. Cancer Res, 57, 1043-6.
- Veikkola T, Alitalo K (1999). VEGFs, receptors and angiogenesis. Semin Cancer Biol, 9, 211-20. https://doi.org/10.1006/scbi.1998.0091
- Wang GS (1989). Medical uses of mylabris in ancient China and recent studies. J Ethnopharmacol, 26, 147-62. https://doi.org/10.1016/0378-8741(89)90062-7
Cited by
- ER81-shRNA Inhibits Growth of Triple-negative Human Breast Cancer Cell Line MDA-MB-231 In Vivo and in Vitro vol.13, pp.5, 2012, https://doi.org/10.7314/APJCP.2012.13.5.2385
- Norcantharidin inhibits tumor angiogenesis via blocking VEGFR2/MEK/ERK signaling pathways vol.104, pp.5, 2013, https://doi.org/10.1111/cas.12120
- Endothelial Cell Proliferation and Vascular Endothelial Growth Factor Expression in Primary Colorectal Cancer and Corresponding Liver Metastases vol.16, pp.11, 2015, https://doi.org/10.7314/APJCP.2015.16.11.4549
- Therapeutic arthropods and other, largely terrestrial, folk-medicinally important invertebrates: a comparative survey and review vol.13, pp.1, 2017, https://doi.org/10.1186/s13002-017-0136-0